drugset / Trial / NCT04186442

Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Patient With Overactive Bladder

NCT04186442

Phase 1 Completed 38 enrolled Hugel
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine the efficacy and safety of Botulax® in treatment of Overactive Bladder

Timeline

Start
2020-05-12
Primary completion
2021-04-26
Completion
2021-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Botulinum toxin type A Protein / enzyme biologic

Indications